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Adrenomedullin (ADM) is an angiogenic factor that has also been shown to be a mitogen and a hypoxia survival factor for tumour
cells. These properties point to ADM as a potential promoter of human malignancies, but little data are available concerning the
expression of ADM in human breast cancer. In the present work, we have examined ADM peptide expression in a series of malignant
breast tumours by immunohistochemistry using a newly developed anti-ADM monoclonal antibody. In addition, ADM plasma
concentrations in breast cancer patients and healthy controls were determined by radioimmunoassay. Of the examined breast cancer
samples, 27/33 (82%) showed a moderate to strong staining intensity. ADM-peptide expression in breast tumours was significantly
correlated with axillary lymph node metastasis (P¼0.030). Analysis of ADM plasma concentrations showed no significant difference
between the circulating ADM levels of breast cancer patients and healthy controls. However, a significant positive correlation was
found between tumour size and plasma ADM levels (r¼0.641, P¼0.017). Moreover, ADM levels in breast cancer patients
correlated with the presence of lymph node metastasis (P¼0.002). In conclusion, we have shown for the first time that ADM
peptide is widely expressed in breast cancer and that the degree of expression is associated with lymph node metastasis. ADM
peptide in plasma of breast cancer patients reflects the size of the primary tumour, but is unlikely to be a useful tumour marker for the
detection of breast cancer. Plasma ADM might represent an independent predictor of lymph node metastasis. The clinical
implications of these findings remain to be evaluated.
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Adrenomedullin (ADM) is a 52-amino-acid peptide belonging to
the calcitonin gene peptide superfamily based on its slight
homology with calcitonin gene-related peptide (CGRP) and
amylin. It acts through the G protein-coupled receptor calcitonin
receptor-like receptor (CRLR), with specificity for ADM being
conferred by the receptor-associated modifying protein 2
(RAMP2) (Poyner et al, 2002).
Adrenomedullin has been implicated in the modulation of
various physiological functions, ranging from vasorelaxation to
acting as a regulator of cell growth (Hinson et al, 2000; Nikitenko
et al, 2002). In 1998, we first showed ADM to be potently
angiogenic using the chick chorioallantoic membrane assay (Zhao
et al, 1998), and it has subsequently been shown to be
protumorigenic by a number of groups employing both xenograft
studies (Martinez et al, 2002; Oehler et al, 2002) and blocking
antibodies (Ouafik et al, 2002). Adrenomedullin and cancer have
recently been reviewed (Zudaire et al, 2003).
Adrenomedullin is a hypoxically induced peptide under control
of the hypoxia-inducible transcription factor-1 (HIF-1), as are
several other angiogenic factors such as vascular endothelial
growth factor (VEGF) (Garayoa et al, 2000). We have previously
shown that ADM acts as an antiapoptotic factor, antagonising
hypoxic cell death of tumour cells (Oehler et al, 2001). The
protumorigenic activity of ADM is also in accordance with recent
data that have revealed a clinical significance of ADM over-
expression in malignant human tumours. Thus, increased expres-
sion of ADM mRNA was associated with poor overall survival in
ovarian cancer (Hata et al, 2000) and high Gleason’s scores in
human prostate cancer (Rocchi et al, 2001).
Circulating levels of ADM have been shown to be elevated in
various disease states including solid tumours such as gastro-
intestinal malignancies (Ehlenz et al, 1997). As the ADM peptide is
rapidly secreted once produced in cells (Kitamura et al, 2002), it is
conceivable that ADM peptide in the blood stream of tumour
patients reflects the ADM secretion from the malignancies. An
involvement of ADM in breast cancer has to date not been clearly
documented, however. No data are available concerning ADM
peptide expression in breast malignancies or of circulating ADM
peptide in breast cancer patients.
In this study, we have examined ADM peptide expression in
breast cancers by means of a newly characterised monoclonal
antibody. In addition, the plasma concentrations of ADM in
patients with breast cancer have been determined. We then
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yanalysed if there were associations between ADM expression in
breast cancer tissue or blood and the clinico-pathological proper-
ties of patients. We finally assessed if ADM could have potential as
a tumour marker in breast cancer.
MATERIALS AND METHODS
Materials
Human ADM used as an immunogen was chemically synthesised
by the Cancer Research UK Peptide Synthesis Laboratory,
Lincoln’s Inn Fields, London, UK. The specificity of the resulting
monoclonal antibodies was confirmed against both this material
and commercial human ADM (Bachem (UK) Ltd., St Helens, UK).
The amylin and CGRP used in this study were also purchased from
Bachem (UK) Ltd.
Patients and healthy controls
Tissue samples Breast carcinoma tissues were derived from 33
randomly selected patients who underwent surgery for primary
breast cancer at the Department of Obstetrics and Gynaecology,
University of Freiburg, Germany between the years 1993 and 1999.
Therapy consisted of either a wide local excision or modified
radical mastectomy followed by axillary lymph node dissection. In
all, 12 patients had distant metastasis. The clinicopathological
properties of the patients are presented in Table 2.
Plasma samples Breast cancer patients Preoperative plasma
samples of 20 patients who underwent surgery for primary breast
cancer at the John Radcliffe Hospital, Oxford, UK between
December 1999 and January 2000 were included in the study.
Patients underwent either modified radical mastectomy or a wide
local excision. All patients had an axillary lymph node dissection.
None of the patients had distant metastases. The clinicopatholo-
gical properties of the series are presented in Table 4. All human
tissue was collected with full approval of the local Ethics
Committee (COREC number COO.097 – Analysis of expression
of proteins induced by hypoxia in primary breast cancer) and
patient consent.
Controls Plasma samples from 18 healthy female volunteer
blood donors attending the blood bank at the John Radcliffe
Hospital, Oxford, UK were included in the study.
Preparation of the anti-ADM monoclonal antibody 171
Female Balb/c mice were immunised subcutaneously with 100mgo f
ADM peptide on day 1 followed by three further immunisations of
50mg at fortnightly intervals. The fusion of the antibody-producing
B cells from the immunised murine spleen with an NS-1 myeloma
partner was carried out using a standard method (Harlow and
Lane, 1988). Supernatants from the hybridoma culture were
screened by antibody capture on multiwell plates coated with
ADM. Bound antibodies were detected using a peroxidase-
conjugated goat anti-mouse secondary antibody (Dako, Glostrup,
Denmark). Hybridomas were subsequently screened by Western
blotting against ADM, using peptide from conditioned medium
from previously described Ishikawa cells stably transfected with
the cDNA for the ADM-cDNA (Oehler et al, 2001).
Elisa
A measure of 10mg of protein in 100ml of PBS was added to
individual wells of a 96-well Nunc-Immunot plate (Nalge-Nunc,
Denmark) having a MaxiSorpt surface overnight at room
temperature. Plates were then blocked for 1h in 20% ‘Marvel’ in
PBS at room temperature. After washing, the wells were incubated
with appropriate dilutions of hybridoma supernatant in PBS for 1h
at room temperature, washed and then incubated for a further
hour at room temperature with goat anti-mouse horseradish
peroxidase (DAKO, Denmark) diluted 1/2500 in PBS. Plates were
washed again, blocked with 10% ‘Marvel’ in PBS for 10min,
washed and then treated with 100ml of 3,30,5,50-tetramethylbenzi-
dine (TMB) ligand substrate system for ELISA (Sigma, Poole, UK)
for periods of up to 30min. Reactions were quenched with 50mlo f
0.5 M sulphuric acid and the absorbance was read at 450nm.
Western blot analysis
For immunoblotting, proteins were resolved by SDS–PAGE in a
10% gel under reducing conditions and transferred onto
Immobilon PVDF membranes (Immobilon PVDF – Millipore,
Watford, UK) by semidry electroblotting. The PVDF membrane
was blocked in PBS containing 0.1% Tween-20 and 5% nonfat milk
before applying the monoclonal antibody 171 in a 1:500 dilution
for 1h. After washing in TBS containing 0.1% Tween, binding was
visualised by a horseradish peroxidase-conjugated goat anti-mouse
antibody (Dako, Glostrup, Denmark) followed by chemilumines-
cence detection with ECL Western blotting reagents (Amersham,
Little Chalfont, UK).
Adrenomedullin-transfected RL95.2 cells
Stable transfection of the endometrial carcinoma cell line RL95.2
with the cDNA for ADM followed by the selection of the ADM
overexpressing cell clones RL-ADM1 and RL-ADM2 has been
previously published (Oehler et al, 2002).
For immunostaining, the transfected cells were fixed in 10%
neutral-buffered formalin, pelleted and embedded in paraffin.
Sections (4mm) were cut onto silane-coated slides. These were
stained according to the following protocol for the immunohisto-
chemical analysis of tumour samples.
Immunohistochemistry
Immunohistochemical analysis of tumour samples was performed
according to standard techniques. Briefly, paraffin sections were
deparaffinised in xylene and hydrated through a series of graded
alcohols. Endogenous peroxidase was blocked with 0.3% hydrogen
peroxide and nonspecific binding prevented by incubation with
10% normal horse serum diluted with phosphate-buffered saline
(PBS). The slides were then incubated with the anti-ADM antibody
171 in a titre 1:100 diluted with PBS containing 1% normal horse
serum for 2h at 371C. A commercially available avidin–biotin
immunoperoxidase kit (Vectastain Elite anti-mouse ABC kit,
Vector Laboratories, Burlingame, CA, USA) was then used to
visualise bound antibody. The colour reaction was produced with
DAB in the presence of 0.03% hydrogen peroxide. Counterstaining
was carried out with haematoxylin. Normal kidney tissue was
employed as a positive control, as it is known to express ADM-
peptide consitutively (Asada et al, 1999).
Immunohistochemical staining was evaluated by two indepen-
dent observers using an arbitrary staining score. Staining intensity
was determined on the scale: 0¼none, I¼weak, II¼moderate,
III¼strong.
Radioimmunoassay
Blood samples were collected into chilled tubes with disodium-
EDTA and aprotinin. Plasma was obtained by immediate
centrifugation. The samples were stored at  801C until further
processing.
Plasma ADM concentrations were measured with a commercial
competitive radioimmunoassay (RIA) (Peninsula Laboratories,
Merseyside, UK) following the manufacturer’s instructions. Briefly,
plasma samples were acidified with 1% trifluoroacetic acid (TFA)
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cartridges (Millipore Corp., Waters Chromatography, Milford,
USA) that had been equilibrated with 60% acetonitrile in 1% TFA
and 1% TFA. The cartridges were then washed with 1% TFA and
peptides were eluted with 60% acetonitrile in 1% TFA. The eluates
were lyophilised and resuspended in radioimmunoassay (RIA)
buffer. Assay samples or standard were incubated with rabbit
anti-human ADM 1-52 antiserum overnight at 41C. This
antiserum is highly specific for human ADM and does not
cross-react with rat ADM, human CGRP, amylin, endothelin-1,
alpha atrial natriuretic peptide (1–28) or brain natriuretic peptide-
32.
125I-ADM (15000 counts per minute (c.p.m.)) was added to
each tube and incubated for another 24h. Antibody-bound
ADM was precipitated using goat anti-rabbit antiserum. After
centrifugation, the c.p.m. in the supernatant was measured with
the gamma counter. The concentration of ADM was determined
from a standard curve, which was constructed using serial
dilutions of synthetic ADM. The detection limit was 1pgtube
 1.
All plasma samples were processed as duplicates in a single assay
to avoid interassay variability. The intra-assay coefficient of
variation was 8%.
Statistical analysis
Statistics were performed using the SPSS for Windows software
package (SPSS Inc., Chicago, USA). The Pearson product–moment
correlation was applied for analysis of associations between
variables, and the Mann–Whitney U test and Kruskall–Wallis
ANOVA, respectively, were employed for comparison of groups.
Po0.05 was considered to be statistically significant.
RESULTS
Characterisation of the anti-ADM monoclonal antibody
171
Monoclonal antibodies from the fusion were screened by solid-
state ELISA. Antibody 171 reacted strongly with ADM, but failed to
recognise the related amylin or CGRP peptides (Figure 1A).
Antibody 171 was further found to detect synthetic ADM and the
peptide in the conditioned media of ADM-transfected RL95.2 cells
by Western blotting (Figure 1B). ADM-transfected RL95.2 cells
showed a strong immunohistochemical labelling with this antibody
while RL95.2 cells transfected with the empty vector were
unstained (Figure 1C). Immunohistochemistry of normal kidney
tissue with the antibody 171 stained distal tubules, collecting
tubules and glomerular capillaries as previously described with
anti-ADM polyclonal antisera.
Adrenomedullin peptide expression in breast carcinomas
Of the examined breast cancer samples, 27/33 (82%) showed
moderate to strong staining intensity. Of the remaining samples,
only two tumours were negative for ADM (Table 1). In the breast
malignancies, ADM staining was homogeneous and detectable
mainly in the cytoplasm of the neoplastic cells (Figure 2).
ADM tissue expression and clinicopathologic features of
breast cancer
Patients Patients with axillary lymph node metastasis were found
to have tumours with significantly higher ADM-peptide expression
then patients with no lymphatic metastasis (N1: 2.70 (70.49)
(mean, s.d.) vs N0: 1.89 (71.02)pgml
 1 (mean, s.d.), P¼0.030,
Mann–Whitney U test) (Figure 3). ADM expression in
breast cancers did not correlate with menopausal status, extent
of tumour, distant metastasis, grading, ER or PR expression
(Table 2).
Plasma ADM levels in breast cancer patients and controls
There was no statistically significant difference between ADM
plasma concentrations of breast cancer patients
132.2774.3pgml
 1 (mean, s.d.) vs controls 107.9732.7pgml
 1,
P40.05; Kruskall–Wallis ANOVA) (Table 3). However, when the
patients were stratified for tumour size, patients with larger breast
tumours (ZT2) were found to express significantly higher ADM
concentrations than healthy controls (ZT2: 186.2765.4pgml
 1
(mean, s.d.) vs controls: 107.9732.7pgml
 1 (mean, s.d.);
P¼0.004, Mann–Whitney U test) (Figure 4).
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Figure 1 Characterisation of the anti-ADM monoclonal antibody 171.
(A) Solid-phase ELISA using antibody 171 against ADM (circle), amylin
(square) and CGRP (triangle). (B) Immunoblotting of supernatant from
transfected ADM-overexpressing RL95.2 cell clones and synthetic ADM.
(C) Immunostaining of ADM-overexpressing RL95.2 cell clones and
controls. (Brown indicates immunostaining.)
Table 1 ADM peptide expression in breast carcinomas (IHC score)
ADM expression (IHC score)
Total cases 0 I II III
n¼33 2 (6%) 4 (12%) 11 (33%) 16 (48%)
Adrenomedullin in breast cancer
MK Oehler et al
1929
British Journal of Cancer (2003) 89(10), 1927–1933 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yA B
C D
E F
Figure 2 Immunostaining of breast carcinomas with the anti-ADM
monoclonal antibody 171. (A) Moderate staining ( 100), (B) weak
staining ( 100), (C) strong staining ( 200), (D) moderate staining
( 400), (E) moderate staining ( 1000), (F) strong staining ( 1000).
(Brown indicates immunostaining.)
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Figure 3 ADM expression in breast tumours of patients with (N1) or
without (N0) lymph node metastasis.
Table 2 Clinicopathological features and adrenomedullin (ADM)
peptide expression (IHC score) in breast cancer tissue samples
Clinicopathological
features
a
ADM expression (IHC score)
mean (stdev) P-value
Menopausal status
premenopausal (n¼10) 2.10 (70.99) NS
b
postmenopausal (n¼23) 2.30 (70.88)
Extent of tumour
pT1 (n¼14) 2.14 (71.09) NS
pT2 (n¼11) 2.18 (70.87)
pT3 (n¼2) 2.00 (70.00)
pT4 (n¼6) 2.67 (70.52)
Nodal status
pN0 (n¼18) 1.89 (71.02) 0.030
pN1 (n¼15) 2.70 (70.49)
Metastasis
M0 (n¼21) 2.05 (71.02) NS
M1 (n¼12) 2.58 (70.51)
Grading
G1 (n¼3) 2.33 (70.58) NS
G2 (n¼9) 2.33 (70.70)
G3 (n¼18) 2.11 (71.80)
ER
Neg (n¼5) 2.20 (70.84) NS
Pos (n¼25) 2.24 (70.97)
PR
Neg (n¼8) 2.38 (70.74) NS
Pos (n¼22) 2.18 (71.00)
aWhere total numbers for each variable do not equal 33, data were unavailable.
bNS¼non significant.
Table 3 Adrenomedullin peptide concentration in plasma of normal
controls and breast cancer patients
Group
Plasma ADM (pg/ml)
mean 7s.d. (range) P-value
Normal controls (n¼18) 107.9732.7 (59–192)
Breast cancer patients (n¼20) 132.2774.3 (28–313) NS
a
pT1 (n¼12) 90.9750.1 (28–210) NS
pT2 (n¼7) 182.9769.9 (128–313) 0.004
b
pT3 (n¼1) 209.070.0
aNS¼nonsignificant, P40.05.
bNormal controls vs T2+T3.
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Figure 4 Plasma ADM concentrations of healthy controls vs breast
cancer patients with T1 or X T2 tumours.
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breast cancer patients
When analysing plasma ADM levels and clinicopathologic features
of breast cancer patients, a significant positive correlation between
tumour size and plasma ADM levels was observed (r¼0.641,
P¼0.017, Pearson’s product–moment correlation) (Figure 5).
Consequently, patients with larger tumours had significantly
higher ADM plasma levels than patients with small volume disease
(pT1: 90.9750.1pgml
 1 (mean, s.d.) vs pT2: 182.9769.9pgml
 1
vs pT3: 209.070.0pgml
 1, P¼0.019, Kruskall–Wallis ANOVA)
(Table 4).
Furthermore, ADM levels in breast cancer patients correlated
with the presence of lymph node metastasis (pN0:
81.4735.9pgml
 1 (mean, s.d.) vs pN1:183.1768.1 (pgml
 1);
P¼0.002, Mann–Whitney U test) (Figure 6).
The plasma concentrations of ADM in patients with breast
cancer did not correlate with menopausal state, histological
tumour type, grading or steroid receptor expression (Table 4).
DISCUSSION
In this study, we have prepared an anti-ADM monoclonal antibody
to assess the expression of ADM in malignant breast tissue. To our
knowledge, no commercial monoclonal antibody against ADM is
currently available and most of the previous immunohistochemical
studies have employed polyclonal antisera (Washimine et al, 1995;
Welsch et al, 2002). Our experiments with the antibody 171 have
shown that it is suitable for Western blotting and immunostaining
on formalin-fixed pathological specimens. Immunostaining in
control tissue was comparable to results from previous studies
using polyclonal antisera (Asada et al, 1999).
The series of breast tumours that we have examined shows that
ADM is expressed in the majority of the carcinomas. The intensity
of ADM expression, however, varied considerably in the malig-
nancies. Staining of tumours was usually homogeneous and
cytoplasmic in distribution.
This is the first study reporting ADM expression in breast
cancers. Adrenomedullin immunostaining has previously been
described for normal human and mouse mammary gland tissue
(Jahnke et al, 1997; Welsch et al, 2002). In normal human breast
tissue, both milk ducts as well as lobules were positive for ADM. As
ADM immunopositivity was identified in basal parts of epithelial
cells in glands and secretory granule-like structures were visualised
by electron microscopy in these cells, it was suggested that ADM
might be secreted into the blood stream acting as an endocrine
signal (Jahnke et al, 1997).
In addition to peptide expression, ADM mRNA expression has
also been previously examined in breast tissue. A recent study
found ADM to be preferentially expressed in the terminal end buds
(TEBs) of mammary glands of young rats (Chakravary et al, 2000).
TEBs are composed of highly proliferative cells thought to be most
susceptible to neoplastic transformation. It may therefore be
hypothesised that although ADM is involved in normal mammary
gland development, it may also have a role in breast cancer when
aberrantly expressed.
Analysis of ADM expression and the clinicopathologic features
of breast cancer patients showed that axillary lymph node
metastasis significantly correlated with the intensity of ADM-
peptide expression in tumours. These findings suggest a potential
role of ADM in the development of lymph node metastasis in
breast cancer.
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Figure 5 Correlation between tumour size and plasma ADM in breast
cancer patients.
Table 4 Clinicopathological features and ADM peptide concentration in
plasma of breast cancer patients (n¼20)
Clinicopathological
features
Plasma ADM (pgml
 1)
mean 7s.d. (range) P-value
Menopausal status
premenopausal (n¼3) 167.67131.7 (55–313) NS
a
postmenopausal (n¼17) 126.0764.2 (28–246)
Tumour size
pT1 (n¼12) 90.9750.1 (28–210) 0.019
pT2 (n¼7) 182.9769.9 (128–313)
pT3 (n¼1) 209.070.0
Nodal status
pN0 (n¼10) 81.4735.9 (28–149) 0.002
pN1 (n¼10) 183.1768.1 (63–313)
Histological type
Ductal (n¼18) 126.0775.6 (28–313) NS
Lobular (n¼2) 188.5729.0 (168–210)
Grading
G1 (n¼2) 173.0753.0 (135–210) NS
G2 (n¼12) 105.9765.4 (28–246)
G3 (n¼6) 171.7782.7 (66–313)
ER
Neg (n¼9) 155.87105.7 (60–313) NS
Pos (n¼11) 120.3769.0 (28–246)
aNS¼nonsignificant, P40.05.
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Figure 6 Plasma ADM concentrations in breast cancer patients with
(N1) or without (N0) lymph node metastasis.
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an apoptosis-survival factor, there are different mechanisms by
which ADM might lead to the increased metastatic potential of
malignant cells in breast cancer.
Adrenomedullin has been reported to be a survival factor for
malignant cells under hypoxia or serum deprivation by upregula-
tion of the antiapoptotic factors like Bcl-2 and Stat3 or down-
regulation of proapoptotic factors like Bax and Bid (Oehler et al,
2001; Martinez et al, 2002). Clinical studies have shown that Bcl-2
expression with loss of apoptosis are important determinants of
lymph node metastasis in breast cancer (Sierra et al, 1996). It is
thought that loss of apoptosis allows accumulation of genetic
alterations affecting tumour-suppressor genes or oncogenes,
resulting in the selection of more aggressive cell clones with the
capability of lymphatic spread (Sierra et al, 2000). It is assumed
that lymphatics contain low concentrations of oxygen and do not
provide an adequate matrix for proliferation (Hockel et al, 1999).
Tumour cells overexpressing ADM and possessing antiapoptotic
potential, however, are more likely to be able to proliferate in
lymphatic vascular spaces and in the subcapsular sinus of lymph
nodes as the first step of lymph node metastasis.
Angiogenesis has also been thought to promote lymphatic
spread of breast cancer (Saaristo et al, 2000). Hypoxia due to rapid
tumour growth and defective microcirculation is very common in
breast cancer and is known to be a driving force behind
angiogenesis (Vaupel et al, 1991). Of the many angiogenic
polypeptides now identified it appears that those induced by
hypoxia are key players in tumour angiogenesis. Adrenomedullin
upregulation under hypoxia has been shown to be controlled by
the hypoxia-inducible transcription factor-1 (HIF-1) (Semenza,
2000), which is overexpressed in a high percentage of primary
breast cancers (Zhong et al, 1999).
Adrenomedullin overexpressing tumours are characterised by
an increased vascularity (Oehler et al, 2002). Several studies have
shown that the probability of metastasis is correlated with the
vascular density of primary tumours (Weidner et al, 1991). In
ADM overexpressing breast cancers, increased angiogenesis might
enhance the opportunity of tumour cells to gain access to the
lymphatic system and to metastasise. In addition, the angiogenic
potential of ADM overexpressing cells might increase the
probability of tumour cells trapped in the lymphatic capillaries
to induce neovascularisation and to give rise to macroscopic
tumour growth.
In the immunohistochemical analysis, we were unable to find a
correlation between ADM expression and tumour grade. Other
groups, however, found a significant association between histolo-
gical grading and ADM when analysing ovarian malignancies
(Hata et al, 2000). Whether this observation is tumour-type
specific, or whether we could not detect this association due to the
limited numbers of cases included in our study is unclear.
In the second part of our study, we have analysed the plasma
ADM values of breast cancer patients and healthy controls. The
mean plasma ADM concentration for healthy subjects was
107.9732.7pgml
 1 (mean7s.d.). This value is in accordance to
concentrations described by other groups (Garcia-Unzueta et al,
1998; Cases and Esforzando, 2000). A meta-analysis comparing 17
studies measuring plasma ADM in healthy subjects obtained by
different immunoassays, however, showed a wide range of ADM
concentrations in healthy women (Hinson et al, 2000). This
observation shows that ADM assays still have to be standardised
and that the range of normal ADM plasma concentrations remains
to be defined.
When we analysed plasma ADM levels and clinicopathologic
features of breast cancer patients, a significant positive correlation
between tumour size and plasma ADM levels was observed. These
results suggest that the source of circulating plasma ADM in those
patients were indeed the breast malignancies. Active tumour
growth, hypoxia and the associated overexpression of ADM might
be responsible for the increased production and release of the
peptide. In addition to such properties, ADM might have an
adaptive function for tumours by increasing the intratumoral
blood flow through its well-known vasodilative properties (Hinson
et al, 2000).
Comparing circulating ADM levels of breast cancer patients and
controls, ADM levels of patients with small (T1) cancers were
similar to those of healthy controls. As a result, ADM is unlikely to
be a useful marker with which to screen for breast cancer.
Nevertheless, patients with large tumours (42cm) had sig-
nificantly higher ADM plasma concentrations than healthy
controls or patients with small tumours (2cm). It seems that
malignant breast lesions require a critical size until a significant
increase of secreted ADM is measurable in blood.
Increased expression of circulating ADM in cancer patients has
also previously been described for colon and lung malignancies
(Ehlenz et al, 1997). Furthermore, patients with Cushing’s disease
resulting from pituitary adenomas were found to have significantly
higher circulating ADM levels than healthy controls. After surgical
removal of the adenomas, ADM levels decreased to normal levels,
indicating that the tumours were the main source of circulating
ADM in those patients (Letizia et al, 2000).
We also found axillary lymph node metastasis to be significantly
correlated with increased ADM plasma levels. Although the
incidence of axillary lymph node involvement is well known to
increase as a function of tumour size (Barth et al, 1997), we did not
find this association in our series (data not shown). ADM plasma
levels might therefore be an independent predictor of axillary
lymph node metastasis in breast cancer.
In conclusion, we have shown for the first time that ADM
peptide is widely expressed in breast malignancies. Tissue
expression is associated with lymph node metastasis, possibly
reflecting a more aggressive tumour type. ADM peptide can be
measured in the plasma of breast cancer patients and reflects the
size of the primary tumour. According to our series, plasma ADM
does not distinguish between early disease and healthy controls
and is unlikely to be a useful tumour marker for the detection of
breast cancer. Plasma ADM levels are elevated in patients with
lymph node involvement and may represent an independent
predictor of lymph node metastasis. Further clinical studies appear
justified.
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